cambridge, massachusetts, April 22, 2024 /PRNewswire/ — AltonaThe company, a pioneering company that is pioneering tRNA therapeutics to understand transfer RNA (tRNA) biology and control the protein world to solve disease, today announced that ASGCT) Presented a poster at the 27th Annual General Meeting. May 7th to 11th in baltimore Lecture and two poster presentations at TIDES united states of america Held in 2024 May 14th to 17th digitally and in person boston.
Details of the lecture content are as follows.
ASGCT 27th Annual General Meeting
Poster title: tRNA therapy to treat stop codon disease
Session date and time: May 9th, 12:00 PM to 7:00 PM ET
Presenter: Steven EichhornPh.D., Alltrna Head of Computational and Molecular Biology
Presentation room: exhibition hall
Session Title: Oligonucleotide Therapeutics
Abstract number: 1221
tide united states of america 2024
Lecture title: Manufacturing strategy for chemically modified tRNA
Session date and time: May 17th, 5:00 PM to 5:30 PM ET
Presenter: William KeesmanPh.D., Chief Technology Officer, Alltna
Session Title: Oligonucleotide Chemistry, Manufacturing, and Control
Poster title: Building 3-D homology models to support tRNA structure-based drug design
Presenter: Audrey HughesPh.D., Scientist II, Computational Chemistry, Alltrna
Poster title: Quantification of tissue delivery of tRNA therapeutics in LNP formulations
Presenter: W. George LaiPh.D., Alltrna, Head of Drug Safety and Clinical Pharmacology, DMPK
The poster will be displayed in the exhibition hall during TIDES. united states of america 2024.
About stop codon disease
Stop codon diseases include thousands of rare and common diseases caused by premature termination codons (PTCs), also known as nonsense mutations, where the code for an amino acid mutates into a premature “stop” codon. This produces truncated or truncated protein products that lack or have altered biological activity that causes disease. Approximately 10% of all people with genetic disorders have stop codon disease, which equates to approximately 30 million people worldwide. Alltrna is developing tRNA medicines that can read these PTC mutations and deliver the desired amino acids, thereby restoring full-length protein production.
About Altona
Alltrna unlocks tRNA biology to treat disease. The company’s platform incorporates AI/ML tools to develop and deliver a diverse range of programmable molecules with broad therapeutic potential. Alltrna has an unprecedented opportunity to advance a single tRNA drug to decipher premature stop codons and unify the treatment of a wide range of diseases that share the same underlying genetic mutation. Alltrna was founded in 2018 by Flagship Pioneering. For more information, please visit: www.alltrna.com.
media contact
Jessica Yinglin,PhD, Little Dog Communications Co., Ltd., jessica@litldog.com,+1.858.344.8091
Josephine SorboPhD, Flagship Pioneering, Jzorbo@flagshippioneering.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/alltrna-announces-presentations-at-asgct-27th-annual-meeting-and-tides- usa-2024-302123478.html
source ortona
